OC000459 (also known as OC-000459 or OC-459) is a small molecule inhibitor of the TLR7/8-mediated inflammatory response. It has been studied for its potential therapeutic effects in various autoimmune diseases, including psoriasis and systemic lupus erythematosus (SLE).
Chemical Name
The chemical name of OC000459 is N-[(2S)-2-(3-Fluoro-4-hydroxyphenyl)-2-hydroxyethyl]-4-nitrobenzamide.
Molecular Formula
The molecular formula of OC000459 is C15H13FN2O5.
Formula Weight
The formula weight of OC000459 is 326.27 g/mol.
CAS No.
The CAS number of OC000459 is 851723-84-7.
Top Ten Keywords and Synonyms
Synonyms:
Health Benefits
OC000459 has shown promising results in preclinical studies as a potential treatment for various autoimmune diseases, including psoriasis and SLE. Its mechanism of action involves the inhibition of the TLR7/8-mediated inflammatory response, which is thought to play a significant role in the pathogenesis of these diseases.
Potential Effects
In preclinical studies, OC000459 has demonstrated anti-inflammatory effects by inhibiting the production of cytokines and chemokines involved in the inflammatory response. It has also been shown to reduce disease severity in animal models of psoriasis and SLE.
Product Mechanism
OC000459 works by inhibiting the TLR7/8-mediated inflammatory response. Toll-like receptors (TLRs) are a family of proteins that play a crucial role in the innate immune system's recognition of pathogens. TLR7 and TLR8 are expressed on immune cells and recognize viral RNA, leading to the activation of inflammatory pathways. By inhibiting this pathway, OC000459 suppresses the production of cytokines and chemokines involved in the inflammatory response.
Safety
OC000459 has been well-tolerated in healthy volunteers in phase 1 clinical trials. Adverse events were generally mild and included nausea, headache, and diarrhea. However, further studies are needed to determine its long-term safety profile.
Side Effects
As with any medication, OC000459 may cause side effects. In preclinical studies, some adverse effects have been reported, including liver toxicity and decreased platelet count. Further studies are needed to determine the frequency and severity of these adverse effects in humans.
Dosing Information
The optimal dosing regimen for OC000459 has not yet been established, as it is still being investigated in clinical trials. The pharmacokinetics of the drug have been studied, and it has been shown to have a half-life of approximately 8 hours. However, further studies are needed to determine the most effective dose and dosing schedule.
Conclusion
In conclusion, OC000459 shows promise as a potential treatment for various autoimmune diseases, including psoriasis and SLE. Its mechanism of action involves the inhibition of the TLR7/8-mediated inflammatory response, which plays a significant role in the pathogenesis of these diseases. While it has been shown to be well-tolerated in early clinical trials, further studies are needed to determine its long-term safety profile and optimal dosing regimen
